Blog

July 10, 2026
LDN for Long COVID brain fog - NIH RECOVER trial 2026

LDN for Long COVID Brain Fog: The NIH RECOVER Trial 2026 Evidence

LDN for Long COVID brain fog is now an NIH priority. The 2026 RECOVER-TLC trial is enrolling 1,300 participants to generate FDA-grade evidence. Here's what the microglial suppression mechanism means for high-performing professionals who haven't fully recovered cognitively from COVID.
Do you like it?0
Read more
June 20, 2026
NLRP3 inflammasome Long COVID neuroinflammation - microglial activation and neuroinflammation mechanism

NLRP3 Inflammasome & Long COVID Neuroinflammation: The Master Switch Driving Brain Fog and Fatigue

The NLRP3 inflammasome is now confirmed as the master molecular switch behind Long COVID neuroinflammation, brain fog, chronic fatigue, and mood dysregulation. A landmark 2026 study explains why — and what you can do about it right now.
Do you like it?0
Read more
June 15, 2026
urolithin A mitophagy post-viral immune recovery - pomegranate ellagitannins cellular health

Urolithin A Mitophagy: The Post-Viral Immune Recovery Protocol Backed by 2025 RCT Data

Urolithin A activates PINK1/Parkin mitophagy to clear damaged mitochondria from exhausted immune cells — restoring naive CD8+ T cells and raising the PEM threshold. Here is the full mechanistic breakdown and protocol stack for Long COVID and ME/CFS recovery.
Do you like it?0
Read more
May 16, 2026
EBV reactivation Long COVID microaggregates - blood cells under microscopy showing cellular aggregates

EBV Reactivation & Long COVID Microaggregates: The Dual-Hit Mechanism Driving Chronic Fatigue

EBV reactivation and Long COVID microaggregates create a compounding dual-hit mechanism driving post-viral fatigue in finance professionals. Discover the 4-layer evidence-backed clinical protocol, including the 2026 Wick et al. data showing 78% improvement with combined antiviral and anti-thrombotic therapy.
Do you like it?0
Read more
April 17, 2026
stellate ganglion block Long COVID POTS - autonomic nervous system medical procedure 2026 STAR-CO trial

Stellate Ganglion Block Long COVID POTS: 2026 STAR-CO Trial & Autonomic Reset Protocol (Part 2)

The first dedicated RCT of stellate ganglion block for Long COVID POTS launched in 2026. Here's everything that's changed: the STAR-CO trial protocol, the Frontiers in Neuroscience editorial endorsement, new mechanistic data on catecholamine-driven mitochondrial uncoupling, and the updated clinical protocol for autonomic reset.
Do you like it?0
Read more
April 7, 2026
stellate ganglion block Long COVID dysautonomia - cervical sympathetic nerve block procedure for autonomic reset

Stellate Ganglion Block for Long COVID Dysautonomia: The 2026 STAR-CO Trial Evidence

Stellate ganglion block for Long COVID dysautonomia has entered formal NIH clinical validation in 2026. We break down the STAR-CO trial, the cervical sympathetic mechanism, catecholamine-driven mitochondrial uncoupling, and the full SGB stacking protocol for finance professionals.
Do you like it?0
Read more
April 1, 2026
photobiomodulation Long COVID brain fog - near-infrared light therapy device for cognitive recovery

Photobiomodulation Long COVID Brain Fog: The 2026 Lancet RCT Breakdown

The January 2026 Lancet eClinicalMedicine RCT tested home-based intranasal and transcranial photobiomodulation in Long COVID patients with brain fog. Near-infrared light targets cytochrome c oxidase — the suppressed rate-limiting enzyme of neuronal ATP production — restoring bioenergetic function while dampening microglial neuroinflammation.
Do you like it?0
Read more
March 27, 2026
low dose naltrexone TRPM3 long COVID - NK cell ion channel research

Low Dose Naltrexone TRPM3 Long COVID: The Ion Channel Breakthrough Rewriting Immunology

A landmark 2025 Griffith University study reveals that low dose naltrexone TRPM3 long COVID research has delivered the most mechanistically specific finding yet: LDN restores the faulty ion channel that keeps Long COVID patients bioenergetically stuck.
Do you like it?0
Read more
March 22, 2026
nattokinase for Long COVID - fibrinolytic enzyme microclots recovery

Nattokinase for Long COVID Recovery: The Fibrinolytic Enzyme Dissolving Microclots & Spike Protein Fragments

Nattokinase for Long COVID is emerging as one of the most mechanistically coherent post-viral recovery interventions. Backed by the Tanikawa et al. 2022 spike protein degradation study and Pretorius microclot research, this deep-dive explains the bioenergetic failure cascade and presents a stacked protocol for finance professionals.
Do you like it?0
Read more
1234